AnaCardio press release 2025.01.092025.01.09 / AnaCardio raises USD 19 million to advance first-in-class drug candidate AC01 for heart failure Reports positive results from phase 1b study of AC01 in patients with heart failure and reduce ...
Theolytics Appoints David Apelian MD, PhD, MBA as CEO 2024.12.172024.12.17 / David Apelian MD PhD MBA, an experienced CEO with significant development and regulatory experience in virology and immune-oncology joins Theolytics Dr Apelian joins as the company advances its f ...
Theolytics Doses First Patient in Phase I/IIa Trial of THEO-260 in Ovarian Cancer 2024.11.192024.11.19 / THEO-260 lyses cancer cells and cancer associated fibroblasts whilst alleviating immune suppression in preclinical studies. THEO-260 is a mechanistically novel oncolytic immunotherapy developed to ...
VarmX announces appointment of John Glasspool as CEO 2024.11.122024.11.12 / Leadership team fully strengthened to drive next phase of development Leiden, The Netherlands, 12 november 2024 VarmX, a biotech company developing innovative approaches for the bypass of direc ...
The makings of a good venture capitalist in biotech 2024.10.282024.10.28 / Venturing to the great unknown: venture capitalism in biotech. What are some of the key tools in a venture capitalist’s repertoire? By Bibhash Mukhopadhyay at Sound Bioventures Historically ...
ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1) 2024.10.212024.10.21 / VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ -- ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on developing innovative medicines through the modulation of gene expressi ...
Before founding Sound Bioventures, Mr. Breum was a Senior Partner at Lundbeckfonden Ventures, where he worked for 12 years, and led investments and served as a member of the board of directors in companies including Sanifit (sold to Vifor Pharma), Aura Biosciences (Nasdaq: AURA), Spero Therapeutics (Nasdaq: SPRO), Nexstim (Nasdaq First North: NXTM), Biomup (Euronext: BUP). 2024.09.122024.09.12 / Prior to that, he was CEO of the venture-backed diagnostics company, ilochip A/S (technology sold to DELTA, now FORCE Technology). Before that, Mr Breum worked in the pharmaceutical industry for 15 y ...
Artax Biopharma completes patient recruitment in Phase 2a trial with first-in-class Nck modulator AX-158 2024.08.132024.09.09 / AX-158 has broad potential to treat many autoimmune diseases without causing immunosuppression Psoriasis biomarker panel and PASI scores expected later this year Cambridge, MA, August 13, 2024 ...
Navigating the journey of orphan drug development 2024.06.282024.06.28 / A new drug rarely takes a direct path from idea to patient, especially a first-in-class therapy. For NephroDI Therapeutics, developing a novel approach addressing the critical unmet medical need of a ...
NephroDI Therapeutics Announces Investment by Sound Bioventures to Accelerate Development of NDI-5001 as a Potential First-in-Class Therapy for Pediatric Orphan Kidney Disease 2024.06.202024.09.04 / New funding to take NDI-5001 into and through clinical proof of concept in Congenital Nephrogenic Diabetes Insipidus (NDI) New investment complements previously announced strategic corporate part ...
Sound Bioventures: Putting Scandinavian Biotechs on the Global Stage 2024.06.042024.09.09 / In this keynote presentation from the BioStock Global Forum, Sound Bioventures' Managing Partner Johan Kordel discusses the importance of Scandinavian biotch companies taking a strong international p ...
Evolving to the next phase of viral therapy development 2024.05.012024.05.13 / UK-based Theolytics is about to begin the first clinical trials for one of its cancer-fighting viruses. It’s a major step for any biotech company, often reached only after years of adjusting and read ...
